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Background. Malignant peripheral nerve sheath tumor (MPNST) is a rare and highly aggressive disease with no evidence of effect
from adjuvant therapy. It is further associated with the hereditary syndrome neurofibromatosis type 1 (NF1). Silencing of the
tumor suppressor gene RASSF1A through DNA promoter hypermethylation is known to be involved in cancer development, but
its impact in MPNSTs remains unsettled.
Methods. The RASSF1A promoter was analyzed by methylation-specific PCR in 113 specimens, including 44 NF1-associated
MPNSTs, 47 sporadic MPNSTs, 21 benign neurofibromas, and 1 nonneoplastic nerve sheath control.
Results. RASSF1A methylation was found only in the malignant samples (60%) and identified a subgroup among patients with
NF1-associated MPNST with a poor prognosis. These patients had a mean 5-year disease-specific survival of 27.3 months (95% CI:
17.2–37.4) versus 47.4 months (95% CI: 37.5–57.2) for NF1 patients with unmethylated promoters, P¼ 0.014. In multivariate
Cox regression analysis, methylated RASSF1A remained an adverse prognostic factor independent of clinical risk factors, P¼ .013
(hazard ratio: 5.2; 95% CI: 1.4–19.4).
Conclusion. A considerable number of MPNST samples display hypermethylation of the RASSF1A gene promoter, and for these
tumors, this is the first molecular marker that if validated can characterize a subgroup of patients with inferior prognosis, restricted
to individuals with NF1.
Keywords: methylation, MPNST, NF1, RASSF1A, survival.
Malignant peripheral nerve sheath tumors (MPNSTs) are clas-
sified as soft tissue sarcomas and are believed to originate
from the neural crest–derived Schwann cells or their precur-
sors.1 About half of these tumors arise in patients with the
hereditary disorder neurofibromatosis type 1 (NF1) caused
by germline mutations in the NF1 gene.1 The lifetime risk of
developing MPNSTs among NF1 patients is about 10%,2
whereas the general population risk is very low. MPNSTs are
highly aggressive and invasive, with a resulting poor 5-year
survival rate of 20% – 50%.3,4 The only consensus therapy
for MPNST patients is surgery, whereas adjuvant chemo-
and/or radiotherapy is offered to selected patients. However,
the additional treatment has not improved the survival
rates.5 Some molecular markers have been suggested to
carry prognostic information,5 – 9 but none of them have so
far been implemented in the clinic. However, evaluation of
molecular biomarkers with prognostic value independent of
high-risk clinical factors ought to be considered as routine
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assays guiding the selection of patients who should be of-
fered additional treatment.
MPNSTs commonly display complex karyotypes with fre-
quent structural and numerical alterations,8,10 including recur-
rent gains of whole or parts of chromosome arm 17q and
deletions from 9p. Components of the cell cycle machinery,
such as TP53, CDKN2A, and RB1, frequently show aberrant
gene and protein expression patterns,11 – 15 and growth factor
receptors like ERRB2, EGFR, KIT, and MET are reported ampli-
fied.11,16 – 18 Interestingly, except for biallelic alterations of the
NF1 gene,19,20 few recurrent mutations have been detected in
these tumors, underscored by a recent oncogene mutation sur-
vey where the 238 most frequent cancer mutations in 19 com-
monly activated oncogenes were analyzed in MPNST cell lines
and all were found to be wild type.21 This emphasizes the im-
portance of the NF1 mutations in MPNSTs. NF1 encodes neuro-
fibromin, a GTPase-activating protein functioning among
others as a negative regulator of Ras. Consequently, loss of
NF1 activity leads to hyperactivation of Ras and continuous sig-
naling through the networks of both mitogen-activated protein
kinase and phosphatidylinositol-3 kinase.1 Ras is known to in-
teract with a number of components other than NF1, including
Ras association domain family member 1, isoform A (RASSF1A),
which is one of the most frequently inactivated tumor suppres-
sors identified in cancer.22 Mutations are rarely found in tu-
mors, but reduced RASSF1A expression caused by DNA
hypermethylation has been reported in a variety of tumor
types, including cancers of the lung, liver, breast, prostate,
and testicles, as well as neuroblastomas, schwannomas,23,24
and a few MPNSTs.25,26 The RASSF1A gene encodes a protein re-
sembling Ras effector proteins and has been shown to play im-
portant roles in cell cycle regulation, apoptosis, and
microtubule stability. The current hypothesis is that RASSF1A,
which has no known enzyme activity, functions both as a scaf-
fold protein and by modulating microtubule polymerization.27
Epigenetic changes are frequently seen in the majority of
cancer diseases, and aberrant hypermethylation of gene pro-
moters has been established as a common and important
mechanism for inactivation of tumor suppressor genes. For
MPNSTs, only a limited number of DNA methylation studies
have been reported, and most of them are hampered by inclu-
sion of rather few clinical samples (overview presented in
Table 1). In this study, the methylation status of RASSF1A was
analyzed and related to the quantitative gene expression and
clinical endpoints in a large European series of MPNSTs.
Materials and Methods
Specimens
Collected at 4 European centers, a total of 113 specimens from
105 patients were included in the present study. The material
comprises 91 MPNSTs, 21 neurofibromas, and 1 tumor-free sci-
atic nerve from a chondrosarcoma patient serving as a nonneo-
plastic nerve sheath control (Supplementary Table S1). All
specimens have been examined by at least one pathologist,
and in case of uncertainty of the diagnosis, the samples were
excluded from the study. The mean age at diagnosis for
Table 1. Genes reported analyzed for DNA promoter methylation in
MPNSTs and neurofibromas
Gene MPNST Neurofibroma Reference
CASP8 0/1 0/18 44
DAPK 0/3 0/18 44
0/17 25
FOXD3a 10 26
GSTP1 0/3 0/18 44
1/17 25
MESTa 10 26


























p73 0/3 4/18 44
RASSF1A 3/17 25
RASSF1a 10 26
RB1 1/3 2/18 44
0/17 25
RUNX1a 10 26
SOX10a 10 10 26
THBS-1 2/3 9/18 44
TIMP-3 1/3 6/18 44
TP53 0/3 0/18 44
TSC2a 10 26
WT1a 10 26
aDifferentially methylated gene specifically mentioned in a
genome-wide methylome analysis comparing 10 pooled MPNSTs, 10
pooled neurofibromas, and 6 pooled nonneoplastic Schwann cell
samples.26
bListed as differentially methylated in the genome-wide analysis re-
vealing 3690 genes potentially involved in MPNST development and
progression.26
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patients with malignant disease was 48 years (range: 11–79)
for those with sporadic tumors (n¼ 47) and 33 years (range:
14–70) for patients with NF1 (n¼ 44). The median age for pa-
tients with neurofibromas (n¼ 21) was 26 years (range: 10–
75). The patients were diagnosed during 1973–2008, and sam-
ples were collected from Oslo University Hospital, Norway;
Ska˚ne University Hospital, Lund, Sweden; University Medical
Center Groningen, Netherlands; and the Istituto Ortopedico Riz-
zoli, Bologna, Italy. The Norwegian biobank is registered at the
Institute for Public Health, biobank registry no. 1781. The study
was approved by the regional committee for medical and
health research ethics South East, and patients were included
following informed consent. Sampling, storage, and analysis
of the Swedish material were approved by the Regional Ethics
Committee of Lund University, following informed consent from
the patients. The Dutch material was approved according to the
University Medical Center Groningen, whereas the Rizzoli Insti-
tute Ethics Committee approved the Italian material, and ac-
cording to institutional guidelines, adult patients or guardians
for minors signed the informed consent form.
Methylation Analysis
DNA was extracted either by phenol/chloroform followed by
ethanol precipitation as described by the manufacturer of the
Nucleic Acid Extractor (Applied Biosystems) or by the Qiagen
Allprep DNA/RNA Mini Kit according to the manufacturer’s pro-
tocol. Further, the DNA was treated with sodium bisulfite using
a previously described protocol28 – 30 and/or the Epitect Bisufite
Kit (Qiagen), followed by qualitative and/or quantitative
methylation-specific polymerase chain reaction (MSP and/or
qMSP, respectively).31
The MSP reactions were carried out in a total volume of
25 mL, containing 20 ng of bilsufite-treated template, 1×PCR
Buffer (Qiagen), 0.2 mM deoxyribonucleotide triphosphate
(Roche Diagnostics), 0.8 mM of each primer, and 0.65–1 U Hot-
starTaq DNA Polymerase (Qiagen). Primers were purchased
from Medprobe. The sequences are listed in Supplementary
Table S2 and a schematic drawing of the promoter region
with primer locations is depicted in Supplementary Fig. S1.
Human placental DNA (Sigma-Aldrich) treated with SssI meth-
yltransferase (New England Biolabs) served as a positive control
for the methylated reaction, whereas bisulfite-modified DNA
from normal lymphocytes was used as positive control for
the unmethylated reaction. Water served as a negative control
for both reactions. The PCR products were separated using 2%
agarose gels (BioRad) stained with ethidium bromide
(Sigma-Aldrich) and visualized by UV light using a GeneGenius
gel documentation system (Syngene). The results were inde-
pendently scored by visual inspection by 2 of the authors,
and all methylated samples were verified by a second, indepen-
dent round of MSP.
The RASSF1A gene promoter was further subjected to qMSP
analysis using a protocol previously described.32 Primers and
probe sequences are listed in Supplementary Table S2 and illus-
trated in Supplementary Fig. S1. To normalize for potential var-
iations in the amount of input DNA (30 ng of bisulfite-treated
template), ALUC4 was used as an internal reference.33 DNA
methylation was calculated as percent of methylated reference





Samples with PMR values exceeding the highest values among
the benign neurofibromas and the nonneoplastic nerve sheath
control (ie, PMR. 0) were scored as methylation positive.
Gene Expression Analysis of RASSF1
Total RNA was isolated from 5 neurofibromas and 27 MPNSTs
using Trizol (Invitrogen) and converted to cDNA using the
High Capacity RNA-to-DNA Kit (Applied Biosystems) according
to the manufacturer’s protocol.
Twenty nanograms of cDNA was amplified in a 20-mL reac-
tion volume containing 1×TaqMan Universal PCR Mastermix (Ap-
plied Biosystems) and predesigned 1× TaqMan Gene Expression
Assays (Applied Biosystems; RASSF1, Hs 00200394_m1; RASSF1
isoform A, Hs 00945257_m1) using the following PCR program:
508C for 2 min, 958C for 10 min, then 45 cycles of 958C for 15 s
followed by 608C for 1 min. The quantitative gene expression of
RASSF1/RASSF1A was measured in real time using the 7900 HT
Sequence Detection System (TaqMan, Applied Biosystems). All
samples were analyzed in triplicate, and the median value was
used for further data analyses. Universal Human Reference RNA
(a mixture of total RNA from 10 different cell lines; Agilent) was
used to generate a standard curve, and the quantitative expres-
sion levels of RASSF1 and RASSF1A were normalized against the
mean value of the endogenous controls ACTB (Hs99999903_m1)
and GUSB (Hs99999908_m1).
Statistics
Statistical analyses were performed using the software pack-
age PASW version 18.0 (SPSS). Fisher’s exact test was used for
assessment of associations between categorical variables,
while the Mann-Whitney-Wilcoxon test was used to examine
association between the methylation status of RASSF1A and
continuous variables. Associations to patient outcome was
evaluated only for patients with available tissue from the pri-
mary tumor, and disease-specific survival was used as the end-
point where deaths of MPNST were considered events and
patients who died of other causes were censored at the time
of death. All MPNST cases included in the present study were
monitored closely at the same institution where they were
treated, thus the cause of death could be identified with
great certainty. The survival curves were generated and com-
pared using the Kaplan–Meier method with the Breslow test,
and Cox regression with the Wald test was used to generate
and test uni- and multivariate proportional hazards. P ≤ .05
was considered statistically significant.
Results
Promoter Methylation of RASSF1A in MPNSTs Related to
Clinicopathological Variables
In an initial (qualitative) MSP screening study of several candi-
date genes (not shown), the RASSF1A promoter was found
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methylated in 23 of 44 MPNST samples (52%), in contrast to
complete absence of methylation in 9 neurofibromas and a
normal sciatic nerve (Supplementary Table S1). No associations
were found between RASSF1A methylation and clinicopatho-
logical variables, including NF1 status, grade, localization, or
size of the tumors, or patients’ age, sex, or nationality.
Due to interesting results from survival analyses, we subse-
quently reanalyzed the RASSF1A gene promoter by qMSP and
expanded the sample series to a total of 91 MPNSTs, 21 neuro-
fibromas, and the sciatic nerve. Sixty percent of the MPNSTs
were methylated, whereas all neurofibromas and the sciatic
nerve remained unmethylated (Supplementary Table S1). The
methylation frequency was slightly, but not significantly, higher
among the NF1 patients compared with the non-NF1 patients
(66% and 54%, respectively; P¼ .3). In concordance with the
results from the qualitative analysis, no associations were
found between the presence of quantitatively measured meth-
ylation of the RASSF1A promoter and clinicopathological vari-
ables (Supplementary Table S3).
RASSF1A Methylation Compared With Quantitative Gene
Expression
For samples where RNA was obtainable (n¼ 27), quantitative
gene expression measurements of 2 assays amplifying differ-
ent transcripts of the RASSF1 gene were performed. For MPNSTs,
there was a strong association between promoter hypermethy-
lation and reduced gene expression, P¼ .001 for the most spe-
cific assay, amplifying only RASSF1A (Fig. 1). This effect was
significant both for NF1 (n¼ 15, P¼ .03) and for non-NF1 pa-
tients (n¼ 12, P¼ .003). Both MPNSTs with methylated and
unmethylated RASSF1A promoter had lower expression than
the benign neurofibromas (P¼ .0001 and P¼ .05, respectively),
suggesting that additional mechanisms are involved in silenc-
ing the RASSF1A gene in MPNST.
For the MPNSTs, a borderline significance was seen with the
second assay, between promoter hypermethylation and re-
duced gene expression (P¼ .06; data not shown). In contrast
to the first assay, the second assay amplified several transcript
variants of the RASSF1 gene.
Methylation of RASSF1A in MPNSTs Related to Survival
In the initial MSP (qualitative) analyses, follow-up data for 36
patients with primary tumors were available, and stratification
Fig. 1. The gene expression of RASSF1A (assay Hs 00945257_m1
detecting NM_007182.4, RASSF1A) is significantly downregulated in
MPNSTs with promoter hypermethylation compared with tumors
without RASSF1A methylation, and also in MPNSTs compared with
neurofibromas independently of methylation.
Fig. 2. Disease-specific survival based on RASSF1A promoter
methylation status for (A) patients with NF1-associated MPNSTs and
(B) patients with sporadic disease.
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according to NF1 status suggested that RASSF1A methylation
could distinguish a subgroup of NF1 patients with worse
disease-specific 5-year survival (n¼ 20, P¼ .011). This could
be seen neither among patients with sporadic disease (n¼
16, P¼ .68) nor in the unstratified MPNST patient cohort (n¼
36, P¼ .11) (data not shown). Based on these initial findings,
we subsequently expanded the sample series and used a quan-
titative and more standardized analysis, qMSP. For this analysis,
long-term follow-up data were available for 60 specimens with
primary tumor, out of the 90 MPNST patients included, and we
confirmed that NF1 patients with RASSF1A methylated tumors
(n¼ 20) had a significantly worse prognosis than did patients
with unmethylated tumors (n¼ 12, P¼ .014; Fig. 2A). The
mean disease-specific survival for NF1 patients with methyla-
tion was 27.3 months (95% CI: 17.2 –37.4) compared with
47.4 months (95% CI: 37.5 –57.2) for NF1 patients without
methylated tumors. No prognostic value of RASSF1A could be
found for patients with sporadic disease (n¼ 28, P¼ .85;
Fig. 2B).
A multivariate Cox regression analysis revealed that methyl-
ation status of RASSF1A was the strongest predictor of
disease-specific survival (hazard ratio: 5.2; 95% CI: 1.4–19.4;
P¼ .013) compared with tumor size, metastasis at time of
diagnosis, and tumor location (P¼ .052, P¼ .054, and P¼
.076, respectively; Table 2).
Discussion
The literature on DNA methylation in MPNSTs is limited. Studies
on a handful of genes have been reported (Table 1) in addition
to a recent paper where the methylomes of 10 pooled benign
and 10 pooled malignant tumors were compared.26 Here, we
add a detailed study analyzing the promoter methylation of
RASSF1A.
In a large European series of MPNSTs we have demonstrated
RASSF1A to be commonly methylated in this malignancy
(60%), and at a frequency considerably higher than previously
reported (18%).25 All normal and benign samples were
unmethylated, underscoring that RASSF1A promoter methyla-
tion is cancer specific. Furthermore, expression of the RASSF1A
gene was significantly reduced in MPNST samples with promot-
er hypermethylation compared with unmethylated samples.
This indicates that methylation causes reduced gene activity,
or gene silencing, which is in agreement with reports on other
cancer types.24,34 Notably, however, also the MPNSTs with
unmethylated RASSF1A promoter had significantly lower gene
expression than in benign tumors, indicating that additional
mechanisms of gene regulation are involved. Regulation of mi-
crotubules has been suggested to be one of the essential tumor
suppressor activities of RASSF1A, thereby ensuring and main-
taining chromosomal stability.22,35 The impaired function of
RASSF1A in MPNST might contribute to the increased DNA
copy number variation and complex karyotypes that are key
characteristics of MPNSTs.
RASSF1A methylation has been suggested to be preferential-
ly present in the most aggressive tumors of various kinds,34,36
suggesting that it might serve as a marker for tumor progres-
sion and metastasis. In the current series of MPNSTs, however,
presence of RASSF1A methylation was equally distributed
among primary, relapsed, and metastatic lesions and between
individuals with and without NF1. It was also independent of
tumor size and site (extremities or trunk), as well as the pa-
tient’s country of origin, age, and gender.
Interestingly, survival analyses showed that RASSF1A meth-
ylation in MPNSTs was a surrogate marker for poor prognosis
among NF1 patients only and independently of clinical risk fac-
tors such as tumor size and metastasis. To the best of our
knowledge, no molecular marker in MPNSTs has previously
been shown to discriminate consistently between inferior and
good prognosis selectively for NF1 patients. Clinical factors
such as large tumor size, incomplete resection, and distant me-
tastasis are shown to be associated with inferior prognosis,3,5
which was also true for the present study. However, the multi-
variate survival analyses identified RASSF1A methylation as the
strongest predictor of outcome among these factors, empha-
sizing the clinical potential of our finding. Biomarkers that are
able to predict prognosis could be valuable in decision making
Table 2. Prognostic factors for 5-year disease-specific survival of NF1 patients with MPNST
Univariate Multivariate
Parameter No. of Patients HR 95% CI P HR 95% CI P
RASSF1A 2.899 1.032–8.143 .04 .013
Unmethylated 12 Ref
Methylated 20 5.235 1.413–19.397
Tumor size, cma 30 1.053 0.992–1.118 .09 1.089 0.999–1.187 .05
Tumor location 0.936 0.380–2.309 .87 .08
Nonextremities 15 Ref
Extremities 17 0.336 0.101–1.121
Metastasis at time of diagnosis 4.299 1.458–12.677 .008 .05
No 27 Ref
Yes 5 3.976 0.974–16.233
Abbreviations: HR, hazard ratio; Ref, reference category.
aContinuous variable.
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when considering treatment alternatives. In the case of
MPNSTs, one could argue that NF1 patients with methylated
RASSF1A, predicting inferior prognosis, would benefit from an
extended follow-up protocol and adjuvant treatment. Although
our study includes a large number of specimens, taking into ac-
count the rareness of the disease and the fact that the findings
seem valid only for NF1 patients with MPNST, it results in quite
small statistical categories. Thus, the prognostic value of
RASSF1A promoter methylation needs to be validated in an in-
dependent sample series. Nevertheless, since methylation of
the same gene has been suggested as a prognostic marker
for various tumor types, including different sarcomas,37 – 43
the methylation status of RASSF1A holds great potential to dif-
ferentiate patients with both NF and MPNST into groups of good
and poor prognosis.
Supplementary Material
Supplementary material is available online at Neuro-Oncology
(http://neuro-oncology.oxfordjournals.org/).
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